{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m sacubitril
to a specific field?
Status:
Investigational
Source:
NCT04176133: Phase 2 Interventional Completed Healthy
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tiprelestat [INN]
Source URL:
Class:
PROTEIN
Tiprelestat (Elafin) is a potent Human neutrophil elastase inhibitor. Elafin is identical to the human protein elafin with high specificity for tissue destroying and inflammation promoting proteases. The development program of Elafin is focused on the late stage development of Elafin in major surgery and early stage development in pulmonary arterial hypertension (PAH). Elafin has received orphan drug designations in the USA and the EU for esophageal cancer surgery (ECS) and PAH. Tiprelestat is in phase II clinical trials for the treatment of myocardial reperfusion injury, postoperative inflammation and in phase I clinical trial for the treatment of pulmonary arterial hypertension.
Status:
Investigational
Source:
Leuk Lymphoma. Apr 2011;52(4):587-96.: Phase 3 Human clinical trial Completed Lymphoma, B-Cell/therapy
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00035880: Phase 2/Phase 3 Interventional Completed Graft Vs Host Disease
(1999)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02462928: Phase 3 Interventional Completed Macular Degeneration
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00504608: Phase 1/Phase 2 Interventional Completed Infertility Implantation Failure
(2003)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
FERTIRELIN is an analog of luteinizing hormone releasing factor. The drug has been used since 1981 in Japan to treat various types of reproductive failure in cattle.
Status:
Investigational
Class:
PROTEIN
Depelestat is a small-protein neutrophil elastase (NE) inhibitor. The elastase at the neutrophil surface was fully inhibited by depelestat and formed soluble complexes. The elastase in cystic fibrosis sputum supernatants was inhibited by stoichiometric amounts of depelestat, allowing titration of the protease. But the percentage of inhibition in whole sputum homogenates varied from 50 to 100%. Depelestat could reduce neutrophil trans-epithelial migration and reduce activity released from neutrophils and NE-induced cytokine expression in airway epithelial cells. NE inhibition could be useful in managing neutrophilic airway inflammation in cystic fibrosis.
Status:
Investigational
Source:
NCT03905707: Phase 3 Interventional Active, not recruiting Short Bowel Syndrome
(2019)
Source URL:
Class:
PROTEIN
Glepaglutide (also known as ZP 1848), a long-acting glucagon-like peptide-2 (GLP-2) analog that was developed for patients with reduced or complete loss of intestinal function. In October 2017 - The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted an orphan drug designation to glepaglutide for the treatment of the rare disease short bowel syndrome (SBS). Many people with SBS are dependent on the frequent intake of intravenous fluids and nutrition delivered through a central catheter. Currently, glepaglutide is participating in a phase III clinical trial to determine the safety and efficacy of subcutaneous injection of the drug for the treatment of SBS.
Status:
Investigational
Source:
NCT00278187: Phase 2 Interventional Unknown status Lung Cancer
(2005)
Source URL:
Class:
PROTEIN
